The addition of a GnRH antagonist to luteal E2 priming did not improve oocyte yield or IVF outcomes in patients with DOR. Given similar efficacy and potential cost savings, luteal E2 priming alone may be a sufficient approach. Prospective trials are needed to validate these findings.
Ghofranian et al. (Wed,) studied this question.